



Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





MYD88 Mutation Analysis

Alternative Name

Myeloid Differentiation Primary Response 88

Methodology

Molecular

Test Description

Bi-directional sequencing of exon 5 of the MYD88 gene which includes detection of the common L265P mutation. Testing is approved for specimens from the state of New York.

Clinical Significance

MYD88 mutation is the most common genetic abnormality in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), detected in 40% of cases. Mutations are rare in the germinal center B-cell-like (GCB) subtype, so mutation analysis can be useful to differentiate between the ABC and GCB subtypes. The L265P mutation is present in >90% of Waldenstrom's macroglobulinemia (WM) and has been associated with increased risk of progression to WM in IgM MGUS patients. MYD88 is also implicated in susceptibility to BTK inhibitors in the treatment of B-cell neoplasms. Testing is available separately or in combination with three other contributory genes in the [BTK Inhibitor Primary Susceptibility Panel](#).

Specimen Requirements

- **Peripheral blood:** 5 mL in EDTA tube.
- **Bone marrow:** 2 mL in EDTA tube.
- **FFPE tissue:** Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
- **Fresh tissue:** 0.5 - 1 cm³ in RPMI. Note: not suitable for Freeze & Hold option.
- **Note:** Please exclude biopsy needles, blades, and other foreign objects from transport tubes. These can compromise specimen viability and yield, and create hazards for employees.

Note: Test in DNA-based, suitable for Freeze & Hold option, except for Fresh Tissue samples.

Storage & Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*

81305

New York Approved

Yes

Level of Service

Global

Turnaround Time

7 days

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com

© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.
All other trademarks are the property of their respective owners
Rev. 050624